<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="on humans for the therapy of CMV infections. cytomegalovirus acute/latent" exact="infection" post="congenital infection antiviral agent therapeutic strategies nucleic acid-based therapeutic"/>
 <result pre="for the therapy of CMV infections. cytomegalovirus acute/latent infection congenital" exact="infection" post="antiviral agent therapeutic strategies nucleic acid-based therapeutic approach HCMV"/>
 <result pre="of latency are peripheral monocytes and CD34+ progenitor cells. HCMV" exact="infection" post="causes a broad range of diseases such as pneumonia,"/>
 <result pre="graft rejection of organ transplantation in recipients [8]. Furthermore, congenital" exact="infection" post="is a major problem with HCMV in that it"/>
 <result pre="(2) proteins that modulate the host cell responses for viral" exact="infection" post="(non-structural use) [11]. The viral envelope surrounding the tegument"/>
 <result pre="glycoprotein B, H, L, M, N, and O. CMV productive" exact="infection" post="results in the coordinated synthesis of proteins in three"/>
 <result pre="mainly code for structural proteins. 1.3. CMV Life Cycle CMV" exact="infection" post="will start once a virion attaches a host cell"/>
 <result pre="with specific receptors on the cellular surface. For a lytic" exact="infection" post="pathway, following linking of viral envelope glycoproteins to host"/>
 <result pre="can persist in host cells indefinitely to have a latent" exact="infection" post="pathway. The primary infection may be accompanied by limited"/>
 <result pre="cells indefinitely to have a latent infection pathway. The primary" exact="infection" post="may be accompanied by limited illness and long-term latency"/>
 <result pre="is referred to as the absence of virions, despite the" exact="detection" post="of viral DNA in hosts. In some clinical cases,"/>
 <result pre="rarely causes signs or symptoms in healthy people. Though CMV" exact="infection" post="is usually ignored in healthy people, the diseases can"/>
 <result pre="organ transplant recipients. A mother who acquires an acute CMV" exact="infection" post="during pregnancy can transmit viruses to her baby, and"/>
 <result pre="Congenital Infection and Sequelae CMV is transmitted by close interpersonal" exact="contact" post="such as saliva, semen, urine, breast milk, or vertically"/>
 <result pre="fetus [15,16]. CMV is the leading cause of congenital viral" exact="infection" post="[17,18,19,20]. CMV infection is mostly or mildly asymptomatic among"/>
 <result pre="is the leading cause of congenital viral infection [17,18,19,20]. CMV" exact="infection" post="is mostly or mildly asymptomatic among the general population"/>
 <result pre="population (85%–90%). However, around 10%–15% of infants with the congenital" exact="infection" post="may be at risk of sequelae such as mental"/>
 <result pre="cognitive impairment [25,26,27]. That means the asymptomatic newborns with CMV" exact="infection" post="still have an increased risk for long-term sequelaes, especially,"/>
 <result pre="At present, some antiviral drugs have been approved for the" exact="treatment" post="of CMV infections clinically. Current available drugs for antiviral"/>
 <result pre="used in clinics [17]. Currently, ganciclovir is still the first" exact="treatment" post="of choice for CMV infections. Letermovir has been approved"/>
 <result pre="brincidofovir [37]. Valnoctamide, a neuroactive mood stabilizer which inhibits CMV" exact="infection" post="in the developing brain and attenuates neurobehavioral dysfunctions, was"/>
 <result pre="[39]. It has been clinically applied for CMV prophylaxis or" exact="treatment" post="in hematopoietic stem cell recipients, thoracic organ recipients and"/>
 <result pre="[47]. 4. CMV Inhibition by Nucleic Acid-Based Therapeutic Approaches The" exact="treatment" post="of diseases caused by CMV is quite challenging because"/>
 <result pre="quite challenging because of high mutation rates and latency. Thus," exact="infection" post="is still a serious threat to humans. Fortunately, external"/>
 <result pre="the CRISPR/Cas9 can be a potential antiviral agent for the" exact="treatment" post="of CMV infections. Gergen et al. designed two CRISPR/Cas9"/>
 <result pre="likely to become part of a new approach for the" exact="treatment" post="of CMV infections. Chen et al. utilized three pairs"/>
 <result pre="antibody and cell-mediated immunity to confer protection against HCMV primary" exact="infection" post="through the analysis of the immune response to HCMV."/>
 <result pre="drugs (e.g., ganciclovir, valganciclovir, cidofovir, foscarnet) are applied for the" exact="treatment" post="of CMV acute infections, however, their efficacy is limited"/>
 <result pre="to understand how antiviral agents or therapeutic strategies affect CMV" exact="infection" post="outcomes. Moreover, the development and implications of novel antiviral"/>
 <result pre="7.MarschallM.FreitagM.WeilerS.SorgG.StammingerT.Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for" exact="screening" post="antiviral agentsAntimicrob. Agents Chemother.2000441588159710.1128/AAC.44.6.1588-1597.200010817714 8.LaY.KwonD.E.YooS.G.LeeK.H.HanS.H.SongY.G.Human cytomegalovirus seroprevalence and titers"/>
 <result pre="cytomegalovirus-immune maternal populationAm. J. Obstet. Gynecol.2010202297-e110.1016/j.ajog.2009.11.01820060091 17.DollardS.C.GrosseS.D.RossD.S.New estimates of the" exact="prevalence" post="of neurological and sensory sequelae and mortality associated with"/>
 <result pre="infection: New prospects for prevention and therapyPediatric Clin.20136033534910.1016/j.pcl.2012.12.008 23.YamamotoA.Y.Mussi-PinhataM.M.IsaacM.d.L.AmaralF.R.CARVALHEIROC.G.AragonD.C.MANFREDIA.K.D.S.BoppanaS.B.BrittW.J.Congenital cytomegalovirus" exact="infection" post="as a cause of sensorineural hearing loss in a"/>
 <result pre="a highly immune populationPediatric Infect. Dis. J.201130104310.1097/INF.0b013e31822d964021814153 24.FowlerK.B.BoppanaS.B.Congenital cytomegalovirus (CMV)" exact="infection" post="and hearing deficitJ. Clin. Virol.20063522623110.1016/j.jcv.2005.09.01616386462 25.BoppanaS.B.RossS.A.FowlerK.B.Congenital cytomegalovirus infection: Clinical"/>
 <result pre="25.BoppanaS.B.RossS.A.FowlerK.B.Congenital cytomegalovirus infection: Clinical outcomeClin. Infect. Dis.201357S178S18110.1093/cid/cit62924257422 26.Mussi-PinhataM.M.YamamotoA.Y.BritoR.M.M.IsaacM.d.L.de Carvalhoe OliveiraP.F.BoppanaS.BrittW.J.Birth" exact="prevalence" post="and natural history of congenital cytomegalovirus infection in a"/>
 <result pre="26.Mussi-PinhataM.M.YamamotoA.Y.BritoR.M.M.IsaacM.d.L.de Carvalhoe OliveiraP.F.BoppanaS.BrittW.J.Birth prevalence and natural history of congenital cytomegalovirus" exact="infection" post="in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 27.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital cytomegalovirus"/>
 <result pre="infection in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 27.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital cytomegalovirus" exact="infection" post="following first trimester maternal infection: Symptoms at birth and"/>
 <result pre="Molecular Pathogenesis to InterventionReddehaseM.J.Caister Academic PressNorfolk, UK201319221410.3201/eid1911.131226 36.KrishnaB.A.WillsM.R.SinclairJ.H.Advances in the" exact="treatment" post="of cytomegalovirusBr. Med. Bull.2019ldz03110.1093/bmb/ldz03131580403 37.GriffithsP.New vaccines and antiviral drugs"/>
 <result pre="al.Single-center experience with use of letermovir for CMV prophylaxis or" exact="treatment" post="in thoracic organ transplant recipientsTranspl Infect. Dis.2019e1316610.1111/tid.1316631487755 42.VeitT.MunkerD.KaukeT.ZollerM.MichelS.CeelenF.SchiopuS.BartonJ.ArnoldP.MilgerK.et al.Letermovir"/>
 <result pre="recipientsTranspl Infect. Dis.2019e1316610.1111/tid.1316631487755 42.VeitT.MunkerD.KaukeT.ZollerM.MichelS.CeelenF.SchiopuS.BartonJ.ArnoldP.MilgerK.et al.Letermovir for difficult to treat cytomegalovirus" exact="infection" post="in lung transplant recipientsTransplantation201910.1097/TP.0000000000002886 43.ChemalyR.F.UllmannA.J.StoelbenS.RichardM.P.BornhäuserM.GrothC.EinseleH.SilvermanM.MullaneK.M.BrownJ.et al.Letermovir for cytomegalovirus prophylaxis"/>
 <result pre="cytomegalovirus in hematopoietic-cell transplantationN. Engl. J. Med.20173772433244410.1056/NEJMoa170664029211658 45.HerlingM.SchröderL.AwerkiewS.ChakupurakalG.HoltickU.KaiserR.PfisterH.ScheidC.Di CristanzianoV.Persistent CMV" exact="infection" post="after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative"/>
 <result pre="absence of anti-viral cellular immunityJ. Clin Virol.201674576010.1016/j.jcv.2015.11.03326672492 46.MaertensJ.CordonnierC.JakschP.PoiréX.UknisM.WuJ.WijatykA.SalibaF.WitzkeO.VillanoS.Maribavir for preemptive" exact="treatment" post="of cytomegalovirus reactivationN. Engl. J. Med.20193811136114710.1056/NEJMoa171465631532960 47.PapanicolaouG.A.SilveiraF.P.LangstonA.A.PereiraM.R.AveryR.K.UknisM.WijatykA.WuJ.BoeckhM.MartyF.M.et al.Maribavir for"/>
 <result pre="by ribonuclease P-associated external guide sequencesRNA20192564565510.1261/rna.069682.11830803999 49.LiW.ShengJ.XuM.VuG.P.YangZ.LiuY.SunX.TrangP.LuS.LiuF.Inhibition of murine cytomegalovirus" exact="infection" post="in animals by RNase P-associated external guide sequencesMol. Nucleic"/>
</results>
